Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 5,610.29% | 64.17% | -216.83% | 43.31% | 42.76% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 62.24% | -66.44% | -33.79% | -29.07% | -59.54% |
| Total Other Non-Cash Items | -7,675.01% | -90.52% | 4,896.47% | -49.00% | -47.96% |
| Change in Net Operating Assets | -69.46% | 488.78% | 640.31% | 342.52% | 503.71% |
| Cash from Operations | -86.84% | 30.22% | 51.53% | 48.07% | 43.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 111.27% | 5.36% | -50.13% | -61.23% | -53.48% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 111.27% | 8.31% | -44.68% | -56.46% | -47.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.20% | 318.40% | 114.32% | -7,750.00% | -18.73% |